Adding an anti-obesity medication just one month after behavioral therapy begins-rather than waiting the currently recommended six months-can more than double weight loss for patients who struggle ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.

Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently ...

Both semaglutide and tirzepatide would need big price cuts to be seen as a good buy for the US healthcare system.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

PHILADELPHIA— Adding an anti-obesity medication just one month after behavioral therapy begins—rather than waiting the currently recommended six ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity medications compared to lifestyle modification alone. Results indicate that ...

GLP-1RA discontinuation and lack of reinitiation was more common among patients with obesity and without type 2 diabetes than with type 2 diabetes.

Low-carb and ketogenic diets offer sustainable solutions for chronic disease, enhancing metabolic health and supporting weight loss through dietary changes.

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...